From the Black press
Community · Miami, FL
PIMJETMI® (pimicotinib) Developed by Abbisko Therapeutics and Licensed by Merck KGaA, Darmstadt, Germany Receive U.S. FDA Approval for TGCT
PIMJETMI® (pimicotinib) is a new systemic treatment option for certain U.S. adult patients with symptomatic tenosynovial giant cell tumor (TGCT), demonstrating durable* tumor response with clinically
M
Continue reading
The full story is at The Miami Times.
The Miami Times reported this story. TUEPAC carries the headline and opening so you can find it here; the reporting, photos, and readership stay with the publisher.
Continue at miamitimesonline.com ↗Opens the publisher's site
Stay on this
Follow what you care about and we send a weekly digest, every story linked to its publisher.
More from The Miami TimesAll headlines →
Study: Young women more likely to use prayer and exercise than Plan B to prevent pregnancy
9HApril Ryan’s ‘Notes on a Blacklash’ confronts racial bias in White House press corps
9HCIPC promotes scholar’s article on advancing mutual learning among civilizations through education and AI cooperation
9HHeadline and an excerpt of at most 40 words from the publisher's public feed. This page's canonical URL points to the original at miamitimesonline.com. How we carry publishers' work · Publisher: see your report